Cost-effectiveness analysis of tyrosine kinase inhibitors (erlotinib vs. gefitinib vs. afatinib) in non-small-cell lung cancer
Fitri Nurhayati, Yusi Anggriani, Elisna Syahruddin, Hesty Utami Ramadaniati, Tri Kusumaeni
DOI: 10.7324/JAPS.2021.110411Pages: 088-095
